Novel coronavirus infection SARS-CoV-2 in elderly and senile patients: prevention, diagnosis and treatment. Expert Position Paper of the Russian Association of Gerontology and Geriatrics
O. N. Tkacheva,
Yu. V. Kotovskaya,
L. A. Aleksanyan,
A. S. Milto,
A. V. Naumov,
I. D. Strazhesko,
N. M. Vorobyeva,
E. N. Dudinskaya,
I. P. Malaya,
K. Yu. Krylov,
E. A. Tyukhmenev,
A. V. Rozanov,
V. S. Ostapenko,
T. M. Manevich,
A. Yu. Shchedrina,
F. A. Semenov,
E. A. Mkhitaryan,
N. O. Khovasova,
K. A. Yeruslanova,
N. V. Kotovskaya,
N. V. Sharashkina https://doi.org/10.15829/1728-8800-2020-2601
- Р Р‡.МессенРТвЂВВВВВВВВжер
- РћРТвЂВВВВВВВВнокласснРСвЂВВВВВВВВРєРСвЂВВВВВВВВ
- LiveJournal
- Telegram
- ВКонтакте
- РЎРєРѕРїРСвЂВВВВВВВВровать ссылку
Full Text:
Abstract
A novel coronavirus infection SARS-CoV-2 (COVID19) is especially dangerous for elderly and senile patients. Preventive measures for elderly people should cover three areas: 1) direct prevention of the viral infection, 2) preservation of the functional status and prevention of geriatric syndromes, including the use of social support measures, 3) control of comorbidities. The clinical pattern of COVID-19 in older patients may be atypical, while the mildness of symptoms (no fever, cough, shortness of breath) may not correspond to the severity of the prognosis. Delirium may be the first manifestation of COVID-19, which requires special care in its screening. Management of elderly and senile patients with COVID19 should include measures for delirium prevention, the detection and improvement of nutrition. The risk of malnutrition with sarcopenia increases with hospitalization of a patient, especially when using artificial ventilation, is associated with an unfavorable prognosis during hospitalization, accelerates the progression of senile asthenia and reduces the quality of life. Geriatric assessment is the cornerstone of determining the management of an elderly patient.
About the Authors
O. N. Tkacheva
Российская ассоциация геронтологов и гериатров
Russian Federation
Russian Federation
Yu. V. Kotovskaya
Российская ассоциация геронтологов и гериатров
Russian Federation
Russian Federation
L. A. Aleksanyan
Российская ассоциация геронтологов и гериатров
Russian Federation
Russian Federation
A. S. Milto
Российская ассоциация геронтологов и гериатров
Russian Federation
Russian Federation
A. V. Naumov
Российская ассоциация геронтологов и гериатров
Russian Federation
Russian Federation
I. D. Strazhesko
Российская ассоциация геронтологов и гериатров
Russian Federation
Russian Federation
N. M. Vorobyeva
Российская ассоциация геронтологов и гериатров
Russian Federation
Russian Federation
E. N. Dudinskaya
Российская ассоциация геронтологов и гериатров
Russian Federation
Russian Federation
I. P. Malaya
Российская ассоциация геронтологов и гериатров
Russian Federation
Russian Federation
K. Yu. Krylov
Российская ассоциация геронтологов и гериатров
Russian Federation
Russian Federation
E. A. Tyukhmenev
Российская ассоциация геронтологов и гериатров
Russian Federation
Russian Federation
A. V. Rozanov
Российская ассоциация геронтологов и гериатров
Russian Federation
Russian Federation
V. S. Ostapenko
Российская ассоциация геронтологов и гериатров
Russian Federation
Russian Federation
T. M. Manevich
Российская ассоциация геронтологов и гериатров
Russian Federation
Russian Federation
A. Yu. Shchedrina
Российская ассоциация геронтологов и гериатров
Russian Federation
Russian Federation
F. A. Semenov
Российская ассоциация геронтологов и гериатров
Russian Federation
Russian Federation
E. A. Mkhitaryan
Российская ассоциация геронтологов и гериатров
Russian Federation
Russian Federation
N. O. Khovasova
Российская ассоциация геронтологов и гериатров
Russian Federation
Russian Federation
K. A. Yeruslanova
Российская ассоциация геронтологов и гериатров
Russian Federation
Russian Federation
N. V. Kotovskaya
Российская ассоциация геронтологов и гериатров
Russian Federation
Russian Federation
N. V. Sharashkina
Российская ассоциация геронтологов и гериатров
References
1. Chinese Center for Control and Prevention. http://www.chinacdc.cn/en/COVID19
2. Vital Surveillances: The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) - China, 2020 http://weekly.chinacdc.cn/en/article/id/e53946e2-c6c4-41e9-9a9b-fea8db1a8f51
3. Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? Lancet. 2020 11-17 April; 395(10231):1225-8. https://doi.org/10.1016/S0140-6736(20)30627-9.
4. Porcheddu R, Serra C, Kelvin D, et al. Similarity in Case Fatality Rates (CFR) of COVID-19/SARS-COV-2 in Italy and China J Infect Dev Ctries. 2020 Feb 29;14(2):125-8. https://doi.org/10.3855/jidc.12600.
5. Liu K, Chen Y, Lin R, Han K. Clinical feature of COVID-19 in elderly patients: a comparison with young and middle-aged patients. J Infect. 2020 Mar 11. pii: S0163- 4453(20)30116-X. https://doi.org/10.1016/j.jinf.2020.03.005.
6. Gomes F, Schuetz P, Bounoure L, et al. ESPEN guideline on nutritional support for polymorbid internal medicine patients. Clin Nutr 2018;37:336-53. https://doi.org/10.1016/j.clnu.2017.06.025.
7. Volkert D, Beck AM, Cederholm T, et al. ESPEN guideline on clinical nutrition and hydration in geriatrics. Clin Nutr 2019;38:10- 47. https://doi.org/10.1016/j.clnu.2018.05.024.
8. Barazzoni R, Bischoff SC, Krznaric Z, endorsed by the ESPEN Council. Espen expert statements and practical guidance for nutritional management of individuals with Sars-cov-2 infection. Clinical Nutrition. 2020;39(6):1631-1638. https://doi.org/10.1016/j.clnu.2020.03.022.
9. Tkacheva ON, Kotovskaya YV, Runikhina NK, et al. Clinical guidelines frailty. Part 2. Russian Journal of Geriatric Medicine. 2020;(2):115-30. (In Russ.) https://doi.org/10.37586/2686-8636-2-2020-115-130.
10. Naumov AV, Tkacheva ON. What can apply for the role of basic therapy for chronic pain in comorbid patients? Meditsinskiy sovet = Medical Council. 2018;(6):120-6. (In Russ.) https://doi.org/10.21518/2079-701X-2018-6-120-126.
11. Grant WB, Lahore H, McDonnell SL, et al. Evidence That Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19. Nutrients. 2020 Apr 2;12(4):E988. https://doi.org/10.3390/nu12040988.
12. Poudel-Tandukar K, Poudel KC, Jimba M, et al. Serum 25-hydroxyvitamin d levels and C-reactive protein in persons with human immunodeficiency virus infection. AIDS Res. Hum. Retrovir. 2013;29:528-34. https://doi.org/10.1089/AID.2012.0120.
13. Zhang M, Gao Y, Tian L, et al. Association of serum 25-hydroxyvitamin D3 with adipokines and inflammatory marker in persons with prediabetes mellitus. Clin. Chim. Acta. 2017;468:152- 8. https://doi.org/10.1016/j.cca.2017.02.022.
14. Dancer RC, Parekh D, Lax S, et al. Vitamin D deficiency contributes directly to the acute respiratory distress syndrome (ARDS). Thorax. 2015;70:617-24. https://doi.org/10.1136/thoraxjnl-2014-206680.
15. Thickett DR, Moromizato T, Litonjua AA, et al. Association between prehospital vitamin D status and incident acute respiratory failure in critically ill patients: A retrospective cohort study. BMJ Open Respir. Res. 2015;2:e000074. https://doi.org/10.1136/bmjresp-2014-000074.
16. Wimalawansa SJ. Global epidemic of coronavirus - COVID-19: What we can do to minimize risks. Eur. J. Biomed. Pharm. Sci. 2020;7:432-8.
17. Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic. J Am Coll Card Mar. 2020 May 12;75(18):2352-71. https://doi.org/10.1016/j.jacc.2020.03.031.
18. Rossi GP, Sanga V, Barton M. Elife Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients. 2020 Apr 6;9:e57278. https://doi.org/10.7554/eLife.57278.
19. Danser AHJ, Epstein M, Batlle D. Renin-Angiotensin System Blockers and the COVID-19 Pandemic. At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers Hypertension. 2020;75:1382-5.
20. HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19. https://www.acc.org/latest-incardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statementaddresses-concerns-re-using-raas-antagonists-in-COVID-19.
21. Liu Y, Huang F, Xu J, et al. Anti-hypertensive Angiotensin II receptor blockers associated to mitigation of disease severity in elderly COVID-19 patients. medRxiv 2020.03.20.20039586; https://doi.org/10.1101/2020.03.20.20039586.
22. Zhang P, Zhu L, Cai J, et al. Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19. Circulation Research. 2020. https://doi.org/10.1161/circresaha.120.317134.
23. Arutyunov GP, Koziolova NA, Tarlovskaya EI, et al. Consensus of experts of the Eurasian Association of therapists on some new mechanisms of COVID-19 pathogenesis: focus on hemostasis, issues of hemotransfusion and blood gas transport system. Kardiologiya. 2020;60(6). (In Russ.) https://doi.org/10.18087/cardio.2020.5.n1132.
24. Gupta R, Ghosh A, Singh AK, Misra F. Clinical Considerations for Patients With Diabetes in Times of COVID-19 Epidemic. Diabetes Metab Syndr. 2020;14(3):211-2. https://doi.org/10.1016/j.dsx.2020.03.002.
25. Zhao Q, Meng M, Kumar R, et al. The Impact of COPD and Smoking History on the Severity of Covid-19: A Systemic Review and MetaAnalysis. J Med Virol. 2020 Apr 15. https://doi.org/10.1002/jmv.25889.
26. Tal-Singer R, Crapo JD. COPD at the time of COVID-19: a COPD Foundation perspective. Chronic Obstr Pulm Dis. 2020;7(2):73-5. https://doi.org/10.15326/jcopdf.7.2.2020.0149.
27. Updated: WHO Now Doesn’t Recommend Avoiding Ibuprofen For COVID-19 Symptoms. https://www.sciencealert.com/whorecommends-to-avoid-taking-ibuprofen-for-covid-19-symptoms.
28. EMA gives advice on the use of non-steroidal anti-inflammatories for COVID-19. https://www.ema.europa.eu/en/news/ema-givesadvice-use-non-steroidal-anti-inflammatories-covid-19.
29. Hunt R, Lazebnik LB, Marakhouski YC, et al. International Consensus on Guiding Recommendations for Management of Patients with Nonsteroidal Anti-inflammatory Drugs Induced Gastropathy-ICON-G. Euroasian J Hepatogastroenterol, 2018;8(2):148-60.
30. Tkacheva ON, Ostroumova OD, Kotovskaya YuV, et al. Deprescribing of proton pump inhibitors in elderly and senile patients. Clinical pharmacology and therapy. 2019;28(1):70-4. (In Russ.) https://doi.org/10.32756/0869-5490-2019-1-70-74.
31. Zhang S, Qing Q, Bai Y, et al. Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy: a systematic review and meta-analysis. Dig Dis Sci. 2013 Jul;58(7):1991-2000. https://doi.org/10.1007/s10620-013-2606-0.
32. Tajima K, Hattori T, Takahashi H, et al. Rebamipide suppresses TNF-α production and macrophage infiltration in the conjunctiva. Vet Ophthalmol. 2018 Jul;21(4):347-52. https://doi.org/10.1111/vop.12510. Epub 2017 Dec 18.
33. Fukuda K, Ishida W, Tanaka H, et al. Inhibition by rebamipide of cytokine-induced or lipopolysaccharide-induced chemokine synthesis in human corneal fibroblasts. Br J Ophthalmol. 2014 Dec;98(12):1751-5. https://doi.org/10.1136/bjophthalmol-2014-305425.
34. Fu R, Jiang Y, Zhou J, Zhang J. Rebamipide ophthalmic solution modulates the ratio of T helper cell 17/regulatory T cells in dry eye disease mice. Mol Med Rep. 2019 May;19(5):4011-8. https://doi.org/10.3892/mmr.2019.10068.
35. Lee SY, Kang EJ, Hur GY, et al. The inhibitory effects of rebamipide on cigarette smoke-induced airway mucin production. Respir Med, 2006;100(3):503-11. https://doi.org/10.1016/j.rmed.2005.06.006.
36. Clerkin KJ, Fried JA, Raikhelkar J, et al. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease. Circulation 2020; https://doi.org/10.1161/CIRCULATIONAHA.120.046941.
37. Shen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 2020;395(10223):507-5.
38. Norman DC. Fever in the elderly. Clinical Infectious Diseases. 2000;31(1):148-51 https://doi.org/10.1086/313896.
39. Shahid Z, Kalayanamitra R, McClafferty B, et al.COVID-19 and Older Adults: What We Know. J Am Geriatr Soc. 2020 May;68(5):926-9. https://doi.org/10.1111/jgs.16472.
40. Atypical Covid-19 presentations in older people - the need for continued vigilance. https://www.bgs.org.uk/blog/atypical-covid-19-presentations-in-older-people-the-need-for-continuedvigilance.
41. Coronavirus: Managing delirium in confirmed and suspected cases. https://www.bgs.org.uk/resources/coronavirusmanaging-delirium-in-confirmed-and-suspected-cases.
42. Singer P, Blaser AR, Berger MM, et al. ESPEN guideline on clinical nutrition in the intensive care unit. Clin Nutr. 2019;38:48-79. https://doi.org/10.1016/j.clnu.2018.08.037.
43. Bauer J, Biolo G, Cederholm T, et al. Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE Study Group. J Am Med Dir Assoc. 2013;14(8):542-59. https://doi.org/10.1016/j.jamda.2013.05.021.
44. Deutz NE, Bauer JM, Barazzoni R, et al. Protein intake and exercise for optimal muscle function with aging: recommendations from the ESPEN Expert Group. Clin Nutr. 2014;33(6):929-36. https://doi.org/10.1016/j.clnu.2014.04.007.
45. Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up. JACC. 2020; https://doi.org/10.1016/j.jacc.2020.04.031.
46. Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID‐19. J Thromb Haemost. 2020;18(5):1023-1026. https://doi.org/10.1111/jth.14810.
47. Dolhnikoff M, Duarte-Neto AN, Monteiro RAA, et al. Pathological evidence of pulmonary thrombotic phenomena in severe COVID19. J Thromb Haemost. 2020; https://doi.org/10.1111/JTH.14844.
48. Carsana L, Sonzogni A, Nasr A. Pulmonary post-mortem findings in a large series of COVID-19 cases from Northern Italy. https://doi.org/10.1101/2020.04.19.20054262.
49. Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;1-10. https://doi.org/10.1007/s00134-020-06062-x
50. Klok F, Kruip M, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145-147. https://doi.org/10.1016/j.thromres.2020.04.013.
51. Menter T, Haslbauer J, Nienhold R, et al. Post-mortem examination of COVID19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings of lungs and other organs suggesting vascular dysfunction. Histopathology. May 2020. https://doi.org/10.1111/his.14134. Online ahead of print.
52. Tang N, Li D., Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18:844-7. https://doi.org/10.1111/jth.14768.
53. Llitjos J, Leclerc M, Chochois C, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost. April 2020. https://doi.org/10.1111/jth.14869.
54. Paranjpe I, Fuster V, Lala A, et al. Association of Treatment Dose Anticoagulation with In-Hospital Survival Among Hospitalized Patients with COVID-19. Journal of the American College of Cardiology. May 2020. https://doi.org/10.1016/j.jacc.2020.05.001.
55. Koyama N, Sasabe H, Miyamoto G. Involvement of Cytochrome P450 in the Metabolism of Rebamipide by the Human Liver. Xenobiotica. 2002 Jul;32(7):573-86. https://doi.org/10.1080/00498250210130591.
56. Liverpool Drug Interaction Group. Interactions with Experimental COVID-19 Therapies. https://www.covid19-druginteractions.org.
57. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Heart J. 2020;41:543-603. https://doi.org/10.1093/eurheartj/ehz405.
58. Kompanje EJO, Piers RD, Benoit DD. Causes and consequences of disproportionate care in intensive care medicine. Curr Opin Crit Care. 2013;19:630-35. https://doi.org/10.1097/MCC.0000000000000026.
59. EuGMS Task Force on COVID-19. Topic 4. Ethical principles concerning proportionality of critical care during the 2020 COVID19 pandemic in Belgium: advice by the Belgian Society of Intensive care medicine. https://www.eugms.org.
60. COVID-19 rapid guideline: critical care in adults. https://www.nice.org.uk/guidance/ng159.
61. Kunz R, Minder M. COVID-19 pandemic: palliative care for elderly and frail patients at home and in residential and nursing homes. Swiss Med Wkly. 2020 Mar 24;150:w20235. https://doi.org/10.4414/smw.2020.20235. eCollection 2020 Mar 23.
62. Analytical bulletin of the higher school of economics on the economic and social consequences of coronavirus in Russia and in the world, dated May 14, 2020. (In Russ.) https://www.hse.ru/mirror/pubs/share/364606313.pdf.
63. Statement - Invest in the overlooked and unsung: build sustainable people-centred long-term care in the wake of COVID-19. http://www.euro.who.int/en/media-centre/sections/statements/2020/statement-invest-in-the-overlooked-andunsung-build-sustainable-people-centred-long-term-care-inthe-wake-of-covid-19.
Review
For citations:
Tkacheva O.N., Kotovskaya Yu.V., Aleksanyan L.A., Milto A.S., Naumov A.V., Strazhesko I.D., Vorobyeva N.M., Dudinskaya E.N., Malaya I.P., Krylov K.Yu., Tyukhmenev E.A., Rozanov A.V., Ostapenko V.S., Manevich T.M., Shchedrina A.Yu., Semenov F.A., Mkhitaryan E.A., Khovasova N.O., Yeruslanova K.A., Kotovskaya N.V., Sharashkina N.V. Novel coronavirus infection SARS-CoV-2 in elderly and senile patients: prevention, diagnosis and treatment. Expert Position Paper of the Russian Association of Gerontology and Geriatrics. Cardiovascular Therapy and Prevention. 2020;19(3):2601. (In Russ.) https://doi.org/10.15829/1728-8800-2020-2601
Views:
4111
ISSN 1728-8800 (Print)
ISSN 2619-0125 (Online)
ISSN 2619-0125 (Online)
Email this article 
